Search

Your search keyword '"Manshu Zou"' showing total 2 results
Start Over Author "Manshu Zou" Topic cantharidin
2 results on '"Manshu Zou"'

1. Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma

Author

Lili Zhou, Manshu Zou, Kun Zhu, Shuangcheng Ning, and Xinhua Xia

Subjects
targeted liposomes, cantharidin, 3-galactosidase-30-stearyl deoxyglycyrrhetinic acid, asialoglycoprotein receptor, glycyrrhetinic acid, hepatocellular carcinoma, Organic chemistry, QD241-441
Abstract

Background: Liver cancer is a common malignant tumor worldwide, and its morbidity and mortality increase each year. The disease has a short course and high mortality, making it a serious threat to human health. Purpose: The objective of this study was to create novel liver-targeting nanoliposomes to encapsulate cantharidin (CTD) as a potential treatment for hepatic carcinoma. Methods: 3-Galactosidase-30-stearyl deoxyglycyrrhetinic acid (11-DGA-3-O-Gal)-modified liposomes (11-DGA-3-O-Gal-CTD-lip) for the liver-targeted delivery of CTD were prepared via the film-dispersion method and characterized. In vitro analyses of the effects on cellular cytotoxicity, cell migration, cell cycle, and cell apoptosis were carried out and an in vivo pharmacokinetics study and tissue distribution analysis were performed. Results: Compared with unmodified liposomes (CTD-lip), 11-DGA-3-O-Gal-CTD-lip showed higher cytotoxicity and increased the inhibition of HepG2 cell migration, but they did not increase the apoptotic rate of cells. The inhibition mechanism of 11-DGA-3-O-Gal-CTD-lip on hepatocellular carcinoma was partly through cell cycle arrest at the S phase. Analysis of pharmacokinetic parameters indicated that 11-DGA-3-O-Gal-CTD-lip were eliminated more rapidly than CTD-lip. Regarding tissue distribution, the targeting efficiency of 11-DGA-3-O-Gal-CTD-lip to the liver was (41.15 ± 3.28)%, relative targeting efficiency was (1.53 ± 0.31)%, relative uptake rate was( 1.69 ± 0.37)%, and peak concentration ratio was (2.68 ± 0.12)%. Conclusion: 11-DGA-3-O-Gal-CTD-lip represent a promising nanocarrier for the liver-targeted delivery of antitumor drugs to treat hepatocellular carcinoma.

Published
2019
Full Text
View/download PDF

2. Development of 11-DGA-3-O-Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma

Author

Kun Zhu, Manshu Zou, Xia Xinhua, Shuangcheng Ning, and Lili Zhou

Subjects
glycyrrhetinic acid, Pharmaceutical Science, 02 engineering and technology, Pharmacology, environment and public health, Analytical Chemistry, lcsh:QD241-441, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, asialoglycoprotein receptor, Pharmacokinetics, targeted liposomes, lcsh:Organic chemistry, Drug Discovery, medicine, Physical and Theoretical Chemistry, Cytotoxicity, Cantharidin, Organic Chemistry, hepatocellular carcinoma, Cell cycle, 021001 nanoscience & nanotechnology, medicine.disease, 3-galactosidase-30-stearyl deoxyglycyrrhetinic acid, chemistry, Chemistry (miscellaneous), Apoptosis, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Molecular Medicine, Nanocarriers, 0210 nano-technology, Liver cancer, cantharidin
Abstract

Background: Liver cancer is a common malignant tumor worldwide, and its morbidity and mortality increase each year. The disease has a short course and high mortality, making it a serious threat to human health. Purpose: The objective of this study was to create novel liver-targeting nanoliposomes to encapsulate cantharidin (CTD) as a potential treatment for hepatic carcinoma. Methods: 3-Galactosidase-30-stearyl deoxyglycyrrhetinic acid (11-DGA-3-O-Gal)-modified liposomes (11-DGA-3-O-Gal-CTD-lip) for the liver-targeted delivery of CTD were prepared via the film-dispersion method and characterized. In vitro analyses of the effects on cellular cytotoxicity, cell migration, cell cycle, and cell apoptosis were carried out and an in vivo pharmacokinetics study and tissue distribution analysis were performed. Results: Compared with unmodified liposomes (CTD-lip), 11-DGA-3-O-Gal-CTD-lip showed higher cytotoxicity and increased the inhibition of HepG2 cell migration, but they did not increase the apoptotic rate of cells. The inhibition mechanism of 11-DGA-3-O-Gal-CTD-lip on hepatocellular carcinoma was partly through cell cycle arrest at the S phase. Analysis of pharmacokinetic parameters indicated that 11-DGA-3-O-Gal-CTD-lip were eliminated more rapidly than CTD-lip. Regarding tissue distribution, the targeting efficiency of 11-DGA-3-O-Gal-CTD-lip to the liver was (41.15 &plusmn, 3.28)%, relative targeting efficiency was (1.53 &plusmn, 0.31)%, relative uptake rate was( 1.69 &plusmn, 0.37)%, and peak concentration ratio was (2.68 &plusmn, 0.12)%. Conclusion: 11-DGA-3-O-Gal-CTD-lip represent a promising nanocarrier for the liver-targeted delivery of antitumor drugs to treat hepatocellular carcinoma.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results